- call +1-201-465-4211
- email sales@mrinsights.biz
Gout is a physical conditions that affects the patient’s ability to move, often also termed as unwalkable disease, and it has been around for centuries.
Scope of the Report:
This report studies the Gout Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Gout Therapeutics market by product type and applications/end industries.
Increased research and development in the field has yielded significantly more effective medications in the recent times, which are recommended to patients on the basis of severity of the condition. Introduction of urate-lowering agents is one of the primary driver of the gout therapeutics market. First line therapies such as Febuxostat and Allopurinol are now replaced urate-lowering agents such as Lesinurad, which help in reducing pain as well as negotiate the risk of joint destruction. The growing popularity of OTC drugs such as Oral colchicine, corticosteroids, and NASAIDs, which are quite effective in moderate gout indications, are also favoring the global gout therapeutics market in the positive direction. Technological advancements in medical imaging is another factor augmenting the demand in the gout therapeutics market. On the other hand, low levels of physician and patient awareness, heavy dependency on generic drugs, and use of CAM for the treatment of gout are restraining factors over the global gout therapeutics market.
At present, the Americas is the largest market for gout therapeutics and is estimated to retain its hold over the market until the end of 2020. The market in this region is growing briskly due to the higher incidences of gout in the US, which results in the growing consumption of gout drugs. In this region, novel therapies like llaris and lesinurad FDC are expected to launch during the forecast period in the US as they have proven benefits over the standard of care. This indicates that novel therapies will have a favorable market potential and good market success during the forecast period.
The global Gout Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Gout Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Takeda Pharmaceutical Company
Novartis
AstraZeneca
GlaxoSmithKline
Merck
Regeneron Pharmaceuticals
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
NSAIDs
Corticosteroids
Colchicine
Urate-Lowering Agents
Market Segment by Applications, can be divided into
Acute Gout
Chronic Gout
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Gout Therapeutics Market Overview
1.1 Product Overview and Scope of Gout Therapeutics
1.2 Classification of Gout Therapeutics by Types
1.2.1 Global Gout Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global Gout Therapeutics Revenue Market Share by Types in 2017
1.2.3 NSAIDs
1.2.4 Corticosteroids
1.2.5 Colchicine
1.2.6 Urate-Lowering Agents
1.3 Global Gout Therapeutics Market by Application
1.3.1 Global Gout Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Acute Gout
1.3.3 Chronic Gout
1.4 Global Gout Therapeutics Market by Regions
1.4.1 Global Gout Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Gout Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Gout Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Gout Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Gout Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Gout Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of Gout Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 Takeda Pharmaceutical Company
2.1.1 Business Overview
2.1.2 Gout Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Takeda Pharmaceutical Company Gout Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Novartis
2.2.1 Business Overview
2.2.2 Gout Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novartis Gout Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 AstraZeneca
2.3.1 Business Overview
2.3.2 Gout Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 AstraZeneca Gout Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 GlaxoSmithKline
2.4.1 Business Overview
2.4.2 Gout Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 GlaxoSmithKline Gout Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 Merck
2.5.1 Business Overview
2.5.2 Gout Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Merck Gout Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 Regeneron Pharmaceuticals
2.6.1 Business Overview
2.6.2 Gout Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Regeneron Pharmaceuticals Gout Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Gout Therapeutics Market Competition, by Players
3.1 Global Gout Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Gout Therapeutics Players Market Share
3.2.2 Top 10 Gout Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Gout Therapeutics Market Size by Regions
4.1 Global Gout Therapeutics Revenue and Market Share by Regions
4.2 North America Gout Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe Gout Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Gout Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America Gout Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Gout Therapeutics Revenue and Growth Rate (2013-2018)
5 North America Gout Therapeutics Revenue by Countries
5.1 North America Gout Therapeutics Revenue by Countries (2013-2018)
5.2 USA Gout Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada Gout Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico Gout Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe Gout Therapeutics Revenue by Countries
6.1 Europe Gout Therapeutics Revenue by Countries (2013-2018)
6.2 Germany Gout Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK Gout Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France Gout Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia Gout Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy Gout Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Gout Therapeutics Revenue by Countries
7.1 Asia-Pacific Gout Therapeutics Revenue by Countries (2013-2018)
7.2 China Gout Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan Gout Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea Gout Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India Gout Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Gout Therapeutics Revenue and Growth Rate (2013-2018)
8 South America Gout Therapeutics Revenue by Countries
8.1 South America Gout Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil Gout Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina Gout Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia Gout Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Gout Therapeutics by Countries
9.1 Middle East and Africa Gout Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Gout Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE Gout Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt Gout Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Gout Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa Gout Therapeutics Revenue and Growth Rate (2013-2018)
10 Global Gout Therapeutics Market Segment by Type
10.1 Global Gout Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global Gout Therapeutics Market Forecast by Type (2018-2023)
10.3 NSAIDs Revenue Growth Rate (2013-2023)
10.4 Corticosteroids Revenue Growth Rate (2013-2023)
10.5 Colchicine Revenue Growth Rate (2013-2023)
10.6 Urate-Lowering Agents Revenue Growth Rate (2013-2023)
11 Global Gout Therapeutics Market Segment by Application
11.1 Global Gout Therapeutics Revenue Market Share by Application (2013-2018)
11.2 Gout Therapeutics Market Forecast by Application (2018-2023)
11.3 Acute Gout Revenue Growth (2013-2018)
11.4 Chronic Gout Revenue Growth (2013-2018)
12 Global Gout Therapeutics Market Size Forecast (2018-2023)
12.1 Global Gout Therapeutics Market Size Forecast (2018-2023)
12.2 Global Gout Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America Gout Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe Gout Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Gout Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America Gout Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Gout Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Gout Therapeutics Picture
Table Product Specifications of Gout Therapeutics
Table Global Gout Therapeutics and Revenue (Million USD) Market Split by Product Type
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
